Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

被引：0
|
作者：
Kohei Motoshima
Yoichi Nakamura
Kazumi Sano
Yoji Ikegami
Takaya Ikeda
Kosuke Mizoguchi
Shinnosuke Takemoto
Minoru Fukuda
Seiji Nagashima
Tetsuya Iida
Kazuhiro Tsukamoto
Shigeru Kohno
机构：
[1] Nagasaki University School of Medicine,Second Department of Internal Medicine
[2] Meiji Pharmaceutical University,Department of Drug Metabolism and Disposition
[3] Japanese Red-Cross Nagasaki Atomic Bomb Hospital,Department of Respiratory Medicine
[4] Nagasaki University Graduate School of Biomedical Sciences,Department of Pharmacotherapeutics
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 72卷
关键词：
Non-small-cell lung cancer; Erlotinib; Chemotherapy; Pharmacokinetics; mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1299 / 1304
页数：5
相关论文
共 50 条
  • [1] PHASE II TRIAL OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS: ADDITIVE ANALYSIS OF PHARMACOKINETICS OF ERLOTINIB
    Ashizawa, Nobuyuki
    Motoshima, Kohei
    Nakamura, Yoichi
    Sano, Kazumi
    Ikegami, Yoji
    Ikeda, Takaya
    MizoguchE, Kosuke
    Takemoto, Shinnosuke
    Fukuda, Minoru
    Nagashima, Seiji
    Iida, Tetsuya
    Tsukamoto, Kazuhiro
    Kohno, Shigeru
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S486 - S486
  • [2] PHASE II TRIAL OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS: ADDITIVE ANALYSIS OF PHARMACOKINETICS OF ERLOTINIB
    Fukushima, A.
    Motoshima, K.
    Shimada, M.
    Kitazaki, T.
    Fukuda, M.
    Hashiguchi, K.
    Nagashima, S.
    Sano, K.
    Nakamura, Y.
    Kohno, S.
    [J]. RESPIROLOGY, 2012, 17 : 81 - 81
  • [3] Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics
    Motoshima, Kohei
    Nakamura, Yoichi
    Sano, Kazumi
    Ikegami, Yoji
    Ikeda, Takaya
    Mizoguchi, Kosuke
    Takemoto, Shinnosuke
    Fukuda, Minoru
    Nagashima, Seiji
    Iida, Tetsuya
    Tsukamoto, Kazuhiro
    Kohno, Shigeru
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (06) : 1299 - 1304
  • [4] PHASE II MULTICENTER TRIAL OF ERLOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
    Isobe, Kazutoshi
    Homma, Sakae
    Takahashi, Kazuhisa
    Koyama, Ryo
    Mori, Kiyoshi
    Kasai, Takashi
    Tominaga, Shigeru
    Kido, Kenji
    Takaya, Hisashi
    Kishi, Kazuma
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1165 - S1166
  • [5] Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations
    Inoue, Yusuke
    Inui, Naoki
    Asada, Kazuhiro
    Karayama, Masato
    Matsuda, Hiroyuki
    Yokomura, Koshi
    Koshimizu, Naoki
    Imokawa, Shiro
    Yamada, Takashi
    Shirai, Toshihiro
    Kasamatsu, Norio
    Suda, Takafumi
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 155 - 161
  • [6] Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations
    Yusuke Inoue
    Naoki Inui
    Kazuhiro Asada
    Masato Karayama
    Hiroyuki Matsuda
    Koshi Yokomura
    Naoki Koshimizu
    Shiro Imokawa
    Takashi Yamada
    Toshihiro Shirai
    Norio Kasamatsu
    Takafumi Suda
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 155 - 161
  • [7] Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
    Matsuura, Shun
    Inui, Naoki
    Ozawa, Yuichi
    Nakamura, Yutaro
    Toyoshima, Mikio
    Yasuda, Kazumasa
    Yamada, Takashi
    Shirai, Toshihiro
    Suganuma, Hideki
    Yokomura, Koji
    Suda, Takafumi
    Chida, Kingo
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (08) : 959 - 963
  • [8] VARIABILITY OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN SERUM DURING ERLOTINIB THERAPY AND ITS CLINICAL IMPLICATIONS: EXPLORATORY ANALYSIS OF A PHASE II STUDY OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATIONS
    Maemondo, Makoto
    Nishio, Makoto
    Yamamoto, Noboru
    Chikamori, Kenichi
    Katakami, Nobuyuki
    Hida, Toyoaki
    Seto, Takashi
    Yoshioka, Hiroshige
    Kozuki, Toshiyuki
    Ohishi, Norihisa
    Tamura, Tomohide
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S384 - S385
  • [9] SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
    Pennell, Nathan A.
    Neal, Joel W.
    Chaft, Jamie E.
    Azzoli, Christopher G.
    Jaenne, Pasi A.
    Govindan, Ramaswamy
    Evans, Tracey L.
    Costa, Daniel B.
    Wakelee, Heather A.
    Heist, Rebecca S.
    Shapiro, Marc A.
    Muzikansky, Alona
    Murthy, Sudish
    Lanuti, Michael
    Rusch, Valerie W.
    Kris, Mark G.
    Sequist, Lecia V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (02) : 97 - +
  • [10] CLINICAL OUTCOMES IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING VERY RARE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Domingues, Pedro Masson
    Montella, Tatiane
    Baldotto, Clarissa Serodio
    Siqueira, Mariana
    Zukin, Mauro
    Ferreira, Carlos Gil
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S169 - S169
12345